SecBot SecBot
DEFA14A ·Filed Nov 6, 2026

OCGN

Ocugen, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed10d 9h ago SEC0001140361-26-042515
Proxy solicitation materials
Actionable Insight • Neutral

Monitor the December 22 special meeting outcome. If the proposal passes, the company will have capacity to issue up to 250 million additional shares, which could lead to future dilution. The repeated adjournments suggest management is still gathering sufficient votes.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$0.9721
T+0 close · Nov 6, 2026 · via day close
Latest settled
−20.48%
T+5 · $0.7730
Vs SPY
−18.79%
α at T+5
Next horizon
T+20
in 21d
  1. T+0 · Nov 9 $0.9721entry
  2. T+1 · 7d ago −2.27%α −1.91% · $0.9500
  3. T+5 · 20h ago −20.48%α −18.79% · $0.7730
  4. T+20 · in 21d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Ocugen filed a DEFA14A notice postponing its reconvened special meeting to December 22, 2026, to vote on a proposal to increase authorized common shares by 250 million. The meeting was originally convened on September 21, 2026, and has been adjourned multiple times. The board unanimously recommends a vote FOR the proposal.

Key Financial Metrics

Meeting
2026-12-22

Key Facts

  • Special meeting reconvened on December 22, 2026 at 8:00 a.m. ET.
  • Proposal 1: increase authorized common shares by 250,000,000 shares.
  • Board unanimously recommends a vote FOR Proposal 1.
  • New record date is October 30, 2026; 339,306,603 shares outstanding as of that date.
  • Adjournment Proposal already approved by stockholders on September 21, 2026.
  • Proxy solicitor: Campaign Management.

Financial Impact

Authorized share increase of 250 million shares; current outstanding shares 339,306,603 as of October 30, 2026.

dilution

Risk Factors

  • Potential dilution if the share increase is approved and subsequently used for capital raises or acquisitions.
  • Repeated meeting adjournments may indicate shareholder resistance to the proposal.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
92% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001140361-26-042515
Document: 0001140361-26-042515-index-headers.html0001140361-26-042515
Document: 0001140361-26-042515-index.html0001140361-26-042515
Document: 0001140361-26-042515.txt0001140361-26-042515

Track record

23 reports on OCGN

Performance horizon

3 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +20.49% at T+20 after the Jun 11, 2026 report. 4 of 6 went positive at some point.

Filters
  1. Nov 10, 20266d ago 8-K Neutral 4/10 Entry $0.9500 to $0.9604 Now $0.7730 −18.63% ▲ +1.09% −0.22% vs SPY
  2. Nov 10, 20266d ago Press Release Neutral 4/10 Entry $0.9500 to $0.9604 Now $0.7730 −18.63% ▲ +1.09% −0.22% vs SPY
  3. Nov 6, 202610d ago DEFA14A Neutral 2/10 Entry $0.9721 to $0.9500 Now $0.7730 −20.48% ▼ −2.27% −1.91% vs SPY
  4. Nov 6, 202610d ago DEFA14A Neutral 3/10 Viewing Entry $0.9721 to $0.9500 Now $0.7730 −20.48% ▼ −2.27% −1.91% vs SPY
  5. Nov 4, 202612d ago 8-K Neutral 4/10 No price data
  6. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $0.8745 to $0.8165 Now $0.7730 −11.61% ▼ −6.63% −2.22% vs SPY
  7. Oct 15, 20264w ago 8-K Neutral 5/10 Entry $0.8137 to $0.7803 Now $0.7730 −5.00% ▼ −4.10% −3.00% vs SPY
  8. Oct 14, 20264w ago 8-K Mixed 5/10 Entry $0.8137 to $0.7803 Now $0.7730 −5.00% ▼ −4.10% −3.00% vs SPY
  9. Oct 9, 20265w ago 144 Neutral 2/10 Entry $0.9472 to $0.8854 Now $0.7730 −18.39% ▼ −6.52% −6.51% vs SPY
  10. Sep 1, 202610w ago Press Release Bullish 7/10 Entry $1.33 to $1.32 Now $0.7730 −41.88% ▼ −0.75% −1.20% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 6, 2026